国际妇产科学杂志 ›› 2024, Vol. 51 ›› Issue (6): 680-683.doi: 10.12280/gjfckx.20240598

• 妇科肿瘤研究:病例报告 • 上一篇    下一篇

卵巢及输卵管子宫内膜异位症恶变为透明细胞癌一例

郭希, 刘思敏, 魏佳, 杨永秀()   

  1. 730000 兰州大学第一临床医学院(郭希,刘思敏,魏佳);兰州大学第一医院妇产科,甘肃省妇科肿瘤临床研究中心(杨永秀)
  • 收稿日期:2024-06-28 出版日期:2024-12-15 发布日期:2024-12-16
  • 通讯作者: 杨永秀,E-mail:yongxiuyang@163.com

Malignant Transformation of Ovarian and Tube Endometriosis into Clear Cell Carcinoma: A Case Report

GUO Xi, LIU Si-min, WEI Jia, YANG Yong-xiu()   

  1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China (GUO Xi, LIU Si-min, WEI Jia); Department of Obstetrics and Gynecology, The First Hospital of Lanzhou University, Gansu Provincial Clinical Research Center for Gynecological Oncology, Lanzhou 730000, China (YANG Yong-xiu)
  • Received:2024-06-28 Published:2024-12-15 Online:2024-12-16
  • Contact: YANG Yong-xiu, E-mail: yongxiuyang@163.com

摘要:

子宫内膜异位症是一种常见的妇科疾病,但发生恶变的概率较低,同时合并卵巢和输卵管子宫内膜异位症恶变为透明细胞癌的概率更低,目前相关报道鲜少。报告1例卵巢及输卵管复合型子宫内膜异位症恶变为透明细胞癌病例,患者因腹胀就诊,影像学检查提示盆腔巨大肿物及腹腔积液,网膜多发结节,考虑转移。遂行卵巢恶性肿瘤细胞减灭术,术后病理活检符合透明细胞癌,癌灶分布于双侧输卵管及右侧卵巢。术后进行静脉化疗,第1周期使用紫杉醇脂质体和卡铂进行化疗,第2周期在原有化疗方案基础上添加贝伐珠单抗进行靶向治疗。现化疗第6个周期,已进行化疗后评估,无明显不良反应,未见肿瘤复发和转移。

关键词: 子宫内膜异位症, 卵巢, 输卵管, 腺癌, 透明细胞, 诊断, 治疗, 预后

Abstract:

Endometriosis is a common gynecological disease, but the probability of malignant transformation is low, and the probability of malignant transformation of ovarian and fallopian tube endometriosis to clear cell carcinoma is lower, and there are few reports on this. Our hospital has found a case of ovarian and fallopian tube compound endometriosis malignant transformation into clear cell carcinoma. The patient was hospitalized due to abdominal distension. Imaging examination revealed huge pelvic masses and ascites, and multiple nodules in the omentum, which were considered to be metastatic. So, ovarian malignant tumor cytoreductive surgery was performed. The postoperative pathological biopsy was consistent with clear cell carcinoma, and the cancer foci were distributed in both fallopian tubes and the right ovary. Intravenous chemotherapy was performed postoperatively, in the first cycle, paclitaxel liposome and carboplatin were used, in the second cycle, bevacizumab was added to the original chemotherapy regimen for targeted therapy. Now the 6th cycle of chemotherapy, post chemotherapy evaluation has been done, there was no obvious adverse reaction, and no tumor recurrence or metastasis was found.

Key words: Endometriosis, Ovary, Fallopian tubes, Adenocarcinoma, clear cell, Diagnosis, Therapy, Prognosis